UCB0599 Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Parkinson's Disease (PD) A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Phase 2 PD0053 Completed NCT046581862020-003265-19 Price D., Khan A., Angers R., Cardenas A., Key-Prato M. et al. Neurology 2022; 98(suppl.18) 74th Annual Meeting of American Academy of Neurology (AAN), April 2-7, 2022; Seattle, USA Parkinson's Disease (PD) An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease Phase 2 PD0055 Ongoing NCT055432522022-500424-30-00
